Trending

age-related macular degeneration

Novartis backs brolucizumab with new head-to-head Eylea trial

Novartis backs brolucizumab with new head-to-head Eylea trial

Novartis is launching a head-to-head trial of its experimental brolucizumab therapy for age-related macular degeneration (AMD) against Bayer/Regeneron’s

X

Novartis backs brolucizumab with new head-to-head Eylea trial

https://pharmaphorum.com/news/novartis-backs-brolucizumab-with-new-head-to-head-eylea-trial/

Regeneron to develop long release Eylea successor

Regeneron to develop long release Eylea successor

Regeneron teams with Ocular Therapeutix to develop next-gen Eylea formulation

X

Regeneron to develop long release Eylea successor

https://pharmaphorum.com/news/regeneron-looks-sustained-release-eye-drug/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com